{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:08Z","timestamp":1794047528132,"version":"4.8.0"},"reference-count":118,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Among the first patients with von Willebrand disease (VWD) described by Eric von Willebrand almost a century ago were young girls and women from a family in the \u00c5land Islands who experienced \u201cgenital hemorrhage\u201d so excessive that it led to exsanguination in five members.1 Only recently has attention focused on the risks and challenges that females with VWD face when experiencing heavy menstrual bleeding, conception, pregnancy, and delivery. The persistent monthly losses with heavy menstrual bleeding and increased demands during pregnancy commonly result in iron deficiency, but the lack of consensus regarding screening and treatment leads to underdiagnosis and undertreatment. While the genetics of VWD are known, female members of affected kindreds are infrequently screened and not considered at risk. Among girls and women with VWD in whom reproductive tract bleeding is the most common symptom, a diagnosis of VWD is often delayed up to a decade or more, leading to significant morbidity, fatigue, depression, iron deficiency, and poor quality of life. Furthermore, there is low certainty regarding effectiveness of current therapies and a lack of prospective trials to guide treatment. Novel therapeutics for inherited bleeding disorders are on the horizon, but women are excluded from studies and have poor access to care. While collaborative hematology-gynecology clinics have improved outcomes, females continue to be excluded from decision-making about their own care. Now, 100 years after the first cases of VWD were reported, it is timely to advocate for better care and management of females with reproductive tract bleeding to assure their future well-being.<\/jats:p>","DOI":"10.3324\/haematol.2024.286059","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T19:56:34Z","timestamp":1767297394000},"page":"67-82","source":"Crossref","is-referenced-by-count":5,"title":["Gynecologic and obstetric management of girls and women with von Willebrand disease"],"prefix":"10.3324","volume":"111","author":[{"given":"Rezan","family":"Abdul-Kadir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret V.","family":"Ragni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"83477","unstructured":"von Willebrand E. Heredit\u00e4r pseudohemophili. Finiska L\u00e4kars\u00e4llskapets Handl. 1926; 67:7-112."},{"key":"83478","doi-asserted-by":"crossref","unstructured":"Ragni MV, Bontempo FA, Hassett AC. von Willebrand disease and bleeding in women. Haemophilia. 1999; 5(5):313-317.","DOI":"10.1046\/j.1365-2516.1999.00342.x"},{"key":"83479","doi-asserted-by":"crossref","unstructured":"Kadir RA, Economides DL, Sabin CA, Pollard D, Lee CA. Assessment of menstrual blood loss and gynecological problems in patients with inherited bleeding disorders. Haemophilia. 1999; 5(1):40-48.","DOI":"10.1046\/j.1365-2516.1999.00285.x"},{"key":"83480","doi-asserted-by":"crossref","unstructured":"Hallberg L, Milsson L. Determination of menstrual blood loss. Scand J Lab Invest. 1964; 16:244-248.","DOI":"10.1080\/00365516409060511"},{"key":"83481","doi-asserted-by":"crossref","unstructured":"Curry N, Bowles L, Clark TJ. Gynecological management of women with inherited bleeding disorders. A UK Haemophilia Centres Doctors\u2019 Organisation Guideline. Haemophilia. 2022; 28(6):917-937.","DOI":"10.1111\/hae.14643"},{"key":"83482","doi-asserted-by":"crossref","unstructured":"Laffan M, Sathar J, Johnsen JM. Von Willebrand disease: diagnosis and treatment of women, and genomic approach to diagnosis. Haemophilia. 2021; 27(Suppl 3):66-74.","DOI":"10.1111\/hae.14050"},{"key":"83483","doi-asserted-by":"crossref","unstructured":"Tosetto A, Castaman G, Rodeghiero F. Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. Blood. 2008; 111(8):3998-4003.","DOI":"10.1182\/blood-2007-08-105940"},{"key":"83484","doi-asserted-by":"crossref","unstructured":"Rodeghiero F, Tosetto A, Abshire T. ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited disorders. J Thromb Haemost. 2010; 8(9):2063-2065.","DOI":"10.1111\/j.1538-7836.2010.03975.x"},{"key":"83485","doi-asserted-by":"crossref","unstructured":"Higham JM, O\u2019Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynecol. 1990; 97(8):734-739.","DOI":"10.1111\/j.1471-0528.1990.tb16249.x"},{"key":"83486","doi-asserted-by":"crossref","unstructured":"Halimeh S, Rott H, Kappert G. PBAC score: an easy-to-use tool to predict coagulation disorders in women with idiopathic heavy menstrual bleeding. Haemophilia. 2016; 22(3):e217-e220.","DOI":"10.1111\/hae.12886"},{"key":"83487","doi-asserted-by":"crossref","unstructured":"Biss TT, Blanchette VS, Clark DS. Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire. J Thromb Haemost. 2010; 8(5):950-956.","DOI":"10.1111\/j.1538-7836.2010.03796.x"},{"key":"83488","doi-asserted-by":"crossref","unstructured":"Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial chart. A validation study. BJOG. 2000; 107(3):320-322.","DOI":"10.1111\/j.1471-0528.2000.tb13225.x"},{"key":"83489","doi-asserted-by":"crossref","unstructured":"Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol. 2004; 190(5):1216-1223.","DOI":"10.1016\/j.ajog.2003.11.015"},{"key":"83490","doi-asserted-by":"crossref","unstructured":"Philipp CS, Faiz A, Heit JA. Evaluation of a screening tool for bleeding disorders in a US multisite cohort of women with menorrhagia. Am J Obstet Gynecol. 2011; 204(3):209.e1-7.","DOI":"10.1016\/j.ajog.2010.10.897"},{"key":"83491","doi-asserted-by":"crossref","unstructured":"Doherty D, Grabell J, Christopherson PA. Variability in the Thrombosis and Haemostasis-Scientific and Standardization Committee endorsed Bleeding Assessment Tool (ISTH-BAT) score with normal aging in healthy females: contributory factors and clinical significance. J Thromb Haemost. 2023; 21(4):880-886.","DOI":"10.1016\/j.jtha.2022.11.045"},{"key":"83492","doi-asserted-by":"crossref","unstructured":"Lavin M, Aguila S, Dalton N. Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Adv. 2018; 2(14):1784-1791.","DOI":"10.1182\/bloodadvances.2018017418"},{"key":"83493","doi-asserted-by":"crossref","unstructured":"Rodeghiero F, Pabinger I, Ragni M. Fundamentals for a systematic approach to mild and moderate inherited bleeding disorders: an EHA Consensus Report. Hemasphere. 2019; 3(4):e286.","DOI":"10.1097\/HS9.0000000000000286"},{"key":"83494","unstructured":"The National Institute for Health and Care Excellence. Heavy menstrual bleeding: assessment and management. Guidance. 2025. Publisher Full Text|"},{"key":"83495","unstructured":"Connell NT, James PD, Brignardello-Petersen R. von Willebrand disease: proposing definitions for future research. Blood Adv. 2021; 5(2):565-569."},{"key":"83496","doi-asserted-by":"crossref","unstructured":"Noone D, Skouw-Rasmussen N, Lanvin M, van Galen KV, Kadir R. Barriers and challenges faced by women with congenital bleeding disorders in Europe: results of a patient survey conducted by the European Haemophilia Consortium. Haemophilia. 2019; 25(3):468-474.","DOI":"10.1111\/hae.13722"},{"key":"83497","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell MJ, Kadir RA, van Galen KPM, Lavin M, EAHAD Women and Girls Working Group. Are women welcome in haemophilia trials?. Haemophilia. 2025; 31(3):575-577.","DOI":"10.1111\/hae.70001"},{"key":"83498","doi-asserted-by":"crossref","unstructured":"Atiq F, Boender J, van Heerde WL. Importance of genotyping in von Willebrand disease to elucidate pathogenic mechanisms and variability in phenotype. Hemasphere. 2022; 6(6):e718.","DOI":"10.1097\/HS9.0000000000000718"},{"key":"83499","doi-asserted-by":"crossref","unstructured":"Sadler B, Minard CG, Haller G. Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations. Blood Adv. 2022; 6(2):420-428.","DOI":"10.1182\/bloodadvances.2021005118"},{"key":"83500","doi-asserted-by":"crossref","unstructured":"Munro MG, Mast AE, Powers JM. The relationship between heavy menstrual bleeding, iron deficiency, and iron deficiency anemia. Am J Obstet Gynecol. 2023; 229(1):1-9.","DOI":"10.1016\/j.ajog.2023.01.017"},{"key":"83501","doi-asserted-by":"crossref","unstructured":"van Galen K, Lavin M, Skouw-Rasmussen N. European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD). European principles of care for women and girls with inherited bleeding disorders. Haemophilia. 2021; 27(5):837-847.","DOI":"10.1111\/hae.14379"},{"key":"83502","doi-asserted-by":"crossref","unstructured":"Baldwin MK, Ahmadzia HK, Bartlett DL. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research to advance the health of people with inherited bleeding disorders with the potential to menstruate. Expert Rev Hematol. 2023; 16(sup1):71-86.","DOI":"10.1080\/17474086.2023.2175660"},{"key":"83503","doi-asserted-by":"crossref","unstructured":"Fedewa SA, Cafuir L, Valentino LA, Koo A, Antun A, Kempton CL. Women and girls\u2019 participation in haemophilia clinical trials. Haemophilia. 2024; 30(6):1440-1443.","DOI":"10.1111\/hae.15101"},{"key":"83504","doi-asserted-by":"crossref","unstructured":"Clearfield E, Kim B, Ford S. A core outcome set for prophylaxis and perioperative treatment of von Willebrand disease: the core VWD initiative. Haemophilia. 2024; 30(6):1357-1365.","DOI":"10.1111\/hae.15122"},{"key":"83505","doi-asserted-by":"crossref","unstructured":"Kadir RA, Tarawah A, Shridhar N, Kulkarni R. Driving improvement of diagnosis and awareness of heavy menstrual bleeding in women among physicians. Haemophilia. 2024; 30(5):1185-1192.","DOI":"10.1111\/hae.15088"},{"key":"83506","doi-asserted-by":"crossref","unstructured":"Huguelet PS, Ayala KA, Beaty L. Knowledge and confidence of obstetrics and gynecology residents in the evaluation and management of heavy menstrual bleeding due to inherited bleeding disorders. Womens Health Rep (New Rochelle). 2024; 5(1):705-711.","DOI":"10.1089\/whr.2024.0086"},{"key":"83507","doi-asserted-by":"crossref","unstructured":"Vo KT, Grooms L, Klima J, Holland-Hall C, O\u2019Brien SH. Menstrual bleeding patterns and prevalence of bleeding disorders in a multidisciplinary adolescent hematology clinic. Haemophilia. 2013; 19(1):71-75.","DOI":"10.1111\/hae.12012"},{"key":"83508","doi-asserted-by":"crossref","unstructured":"Peuranp\u00e4\u00e4 P, Heli\u00f6vaara-Peippo S, Fraser I, Paav\u00f6nen J, Hurskainen R. Effects of anemia and iron deficiency on quality of life in women with heavy menstrual bleeding. Acta Obstet Gynecol Scand. 2014; 93(7):654-660.","DOI":"10.1111\/aogs.12394"},{"key":"83509","doi-asserted-by":"crossref","unstructured":"Castaman G, Katsarou O, Jansen N, Santos S, Escolar G, Berntorp E. Clinical, economic, and health-related quality of life burden associated with von Willebrand disease in adults and children: systematic and targeted literature reviews. Haemophilia. 2023; 29(2):411-422.","DOI":"10.1111\/hae.14655"},{"key":"83510","doi-asserted-by":"crossref","unstructured":"Bruner AB, Joffee A, Duggan AK, Casella JF, Brandt J. Randomised study of cognitive effects of iron supplementation in non-anemic iron-deficient adolescent girls. Lancet. 1996; 348(9033):992-996.","DOI":"10.1016\/S0140-6736(96)02341-0"},{"key":"83511","doi-asserted-by":"crossref","unstructured":"De Loughery TG. Safety of oral and intravenous iron. Acta Haematol. 2019; 142(1):8-12.","DOI":"10.1159\/000496966"},{"key":"83512","doi-asserted-by":"crossref","unstructured":"McCormick M, Hu J, Chandler M, Manuel M, Chrisentery-Singleton T, Ragni MV. Iron ladies: prevalence and risk factors for iron deficiency in women with bleeding disorders. Haemophilia. 2025; 31(3):502-508.","DOI":"10.1111\/hae.70004"},{"key":"83513","doi-asserted-by":"crossref","unstructured":"Stoffel NU, Cercamondi CI, Brittenham G. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women. Lancet Haematol. 2017; 4(11):e524-e533.","DOI":"10.1016\/S2352-3026(17)30182-5"},{"key":"83514","doi-asserted-by":"crossref","unstructured":"Cogan JC, Meyer J, Jian Z, Sholzberg M. Iron deficiency resolution and time to resolution in an American health care system. Blood Adv. 2024; 8(23):6029-6034.","DOI":"10.1182\/bloodadvances.2024013197"},{"key":"83515","doi-asserted-by":"crossref","unstructured":"James A, Ragni MV, Picozzi VJ. ASH Special educational symposium: bleeding disorders in premenopausal women: another public health crisis for hematology. Hematology Am Soc Hematol Educ Program. 2006;474-485.","DOI":"10.1182\/asheducation-2006.1.474"},{"key":"83516","doi-asserted-by":"crossref","unstructured":"Weyand AC, Chaitoff A, Freed GL, Sholzberg M, Choi SW, McGann PT. Prevalence of iron deficiency and iron deficiency anemia in US females aged 12-21 years. 2003-2020. JAMA. 2023; 329(24):2191-2193.","DOI":"10.1001\/jama.2023.8020"},{"key":"83517","doi-asserted-by":"crossref","unstructured":"Mansour D, Hofmann A, Gemzell-Danielsson K. A review of clinical guidelines on the management of iron deficiency and iron deficiency anemia in women with heavy menstrual bleeding. Adv Ther. 2021; 38(1):201-225.","DOI":"10.1007\/s12325-020-01564-y"},{"key":"83518","doi-asserted-by":"crossref","unstructured":"[No authors listed]. Screening and management of bleeding disorders in adolescents with heavy menstrual bleeding. ACOG Committee opinion, number 875. Obstet Gynecol. 2019; 134(3):e71-e83.","DOI":"10.1097\/AOG.0000000000003411"},{"key":"83519","doi-asserted-by":"crossref","unstructured":"Connell NT, Flood VH, Brignardello-Petersen R. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021; 5(1):301-325.","DOI":"10.1182\/bloodadvances.2020003264"},{"key":"83520","unstructured":"The American Society of Hematology. Plan for new ASH clinical practice guidelines on iron deficiency anemia. 2024. Publisher Full Text|"},{"key":"83521","doi-asserted-by":"crossref","unstructured":"Kadir RA, Sabin CA, Pollard D, Lee CA, Economides DL. Quality of life during menstruation in patients with inherited bleeding disorders. Haemophilia. 1998; 4(6):836-841.","DOI":"10.1046\/j.1365-2516.1998.00208.x"},{"key":"83522","doi-asserted-by":"crossref","unstructured":"Srivaths L, Minard CG, O\u2019Brien SH. The spectrum and severity of bleeding in adolescents with low von Willebrand factor-associated heavy menstrual bleeding. Blood Adv. 2020; 4(13):3209-3216.","DOI":"10.1182\/bloodadvances.2020002081"},{"key":"83523","doi-asserted-by":"crossref","unstructured":"von Mackensen S. Quality of life in women with bleeding disorders. Haemophilia. 2011; 17(Suppl 1):33-37.","DOI":"10.1111\/j.1365-2516.2011.02563.x"},{"key":"83524","doi-asserted-by":"crossref","unstructured":"Xu Y, Deforest M, Grabell J, Hopman W, James P. Relative contributions of bleeding scores and iron status on health-related quality of life in von Willebrand disease: a cross-sectional study. Haemophilia. 2017; 23(1):115-121.","DOI":"10.1111\/hae.13062"},{"key":"83525","doi-asserted-by":"crossref","unstructured":"Govorov I, Ekelund L, Chaireti R. Heavy menstrual bleeding and health-associated quality of life in women with von Willebrand disease. Exp Therapeutic Med. 2016; 11(5):1923-1929.","DOI":"10.3892\/etm.2016.3144"},{"key":"83526","doi-asserted-by":"crossref","unstructured":"Wyatt SN, Banahan T, Tang Y, Nadendla K, Szychowski JM, Jenkins TR. Effect of radiofrequency endometrial ablation on dysmenorrhea. J Minim Invasive Gynecol. 2016; 23(7):1163-1166.","DOI":"10.1016\/j.jmig.2016.08.825"},{"key":"83527","doi-asserted-by":"crossref","unstructured":"Kadir RA, Edlund M, von Mackensen S. The impact of menstrual disorders on quality of life in women with inherited bleeding disorders. Haemophilia. 2010; 16(5):832-839.","DOI":"10.1111\/j.1365-2516.2010.02269.x"},{"key":"83528","doi-asserted-by":"crossref","unstructured":"Samuelson-Bannow B, Haley K, Colwill A, Edelman A, Bednarek P, Baldwin M. Adult haematology clinics for menstruating\/ pregnant patients: a single center experience and lessons learned. Haemophilia. 2024; 30(2):564-566.","DOI":"10.1111\/hae.14950"},{"key":"83529","doi-asserted-by":"crossref","unstructured":"Turan P, Gomez K, Kadir RA. Review of interventions and effectiveness for heavy menstrual bleeding in women with moderate and severe von Willebrand disease. Haemophilia. 2024; 31(5):1177-1184.","DOI":"10.1111\/hae.15078"},{"key":"83530","doi-asserted-by":"crossref","unstructured":"Amesse LS, Pfaff-Amesse T, Leonardi R, Uddin D, French JA II. Oral contraceptives and DDAVP nasal spray: patterns of use in managing VWD-associated menorrhagia: a single-institution study. J Pediatr Hematol Oncol. 2005; 27(7):357-363.","DOI":"10.1097\/01.mph.0000173175.95152.95"},{"key":"83531","doi-asserted-by":"crossref","unstructured":"Foster PA. The reproductive health of women with von Willebrand disease unresponsive to DDAVP: results of an international survey (ISTH). Thromb Haemost. 1995; 74(2):784-790.","DOI":"10.1055\/s-0038-1649813"},{"key":"83532","doi-asserted-by":"crossref","unstructured":"Brignardello-Petersen R, Alayli AE, Husainat N. Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature. Blood Adv. 2022; 6(1):228-237.","DOI":"10.1182\/bloodadvances.2021005589"},{"key":"83533","doi-asserted-by":"crossref","unstructured":"Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG. 2004; 111(12):1425-1428.","DOI":"10.1111\/j.1471-0528.2004.00305.x"},{"key":"83534","doi-asserted-by":"crossref","unstructured":"Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. Haemophilia. 2002; 8(6):787-793.","DOI":"10.1046\/j.1365-2516.2002.00678.x"},{"key":"83535","doi-asserted-by":"crossref","unstructured":"Rose SS, Faiz A, Miller CH, Saidi P, Philipp CS. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction. Haemophilia. 2008; 14(3):571-578.","DOI":"10.1111\/j.1365-2516.2008.01655.x"},{"key":"83536","doi-asserted-by":"crossref","unstructured":"Kouides PA, Byams VR, Philipp CS. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol. 2009; 145(2):212-220.","DOI":"10.1111\/j.1365-2141.2009.07610.x"},{"key":"83537","doi-asserted-by":"crossref","unstructured":"Ettinghausen CE, Lassila R, Escolar G. Plasma-derived von Willebrand factor\/factor VIII concentrate (Haemate P) in von Willebrand disease: a systematic review and pharmacovigilance update. Haemophilia. 2025; 31(2):247-262.","DOI":"10.1111\/hae.15138"},{"key":"83538","doi-asserted-by":"crossref","unstructured":"Ragni MV, Machin N, Malec LM. Von Willebrand factor for menorrhagia: a survey and literature review. Haemophilia. 2016; 22(3):397-402.","DOI":"10.1111\/hae.12898"},{"key":"83539","doi-asserted-by":"crossref","unstructured":"Ragni MV, Rothenberger S, Feldman R. Multicenter, randomized, crossover trial comparing recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in von Willebrand disease. Lancet Haematol. 2023; 10(8):e612-e623.","DOI":"10.1016\/S2352-3026(23)00119-9"},{"key":"83540","doi-asserted-by":"crossref","unstructured":"Beelen P, Reinders IMA, Scheepers WFW. Prognostic factors for the failure of endometrial ablation: a systematic review and meta-analysis. Obstet Gynecol. 2019; 134(6):1269-1281.","DOI":"10.1097\/AOG.0000000000003556"},{"key":"83541","doi-asserted-by":"crossref","unstructured":"Brignardello-Petersen R, Alayli EA, Husainat N. Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature. Blood Adv. 2022; 6(1):121-128.","DOI":"10.1182\/bloodadvances.2021005666"},{"key":"83542","doi-asserted-by":"crossref","unstructured":"Eising HP, Punt MC, Leemans JC, Bongers MY. Prophylactic and therapeutic strategies for intraoperative bleeding in women with von Willebrand disease and heavy menstrual bleeding: a systematic review. Blood Rev. 2023; 62:101131.","DOI":"10.1016\/j.blre.2023.101131"},{"key":"83543","doi-asserted-by":"crossref","unstructured":"von Drygalski A, Chowdary P, Kulkarni R. XTEND-1 Trial Group. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med. 2023; 388(4):310-318.","DOI":"10.1056\/NEJMoa2209226"},{"key":"83544","doi-asserted-by":"crossref","unstructured":"Ryu JH, Bauer KA, Schulman S. Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa. J Thromb Haemost. 2023; 21(12):3058-3510.","DOI":"10.1016\/j.jtha.2023.09.009"},{"key":"83545","doi-asserted-by":"crossref","unstructured":"Callahan MU, Negrier C, Pza-Priel I. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021; 137(16):2231-2242.","DOI":"10.1182\/blood.2020009217"},{"key":"83546","doi-asserted-by":"crossref","unstructured":"Yaoi H, Shida Y, Katazawa T, Shima M, Nogami K. Emicizumab improves thrombus formation of type 2A von Willebrand disease under high thrombus formation of type 2A von Willebrand disease under high shear condition. Haemophilia. 2021; 27(2):e194-e203.","DOI":"10.1111\/hae.14272"},{"key":"83547","doi-asserted-by":"crossref","unstructured":"Weyand AC, Flood VH, Shavit JA, Pipe SWS. Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies. Blood Adv. 2019; 3(18):2748-2750.","DOI":"10.1182\/bloodadvances.2019000656"},{"key":"83548","doi-asserted-by":"crossref","unstructured":"Chion A, Byrbe C, Atiq F. The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1. Blood. 2024; 144(13):1445-1456.","DOI":"10.1182\/blood.2024024055"},{"key":"83549","doi-asserted-by":"crossref","unstructured":"Ay C, Pabinger I, Kovacevic KD. The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF\/FVIII in type 2B von Willebrand disease. Blood Adv. 2022; 6(18):5467-5476.","DOI":"10.1182\/bloodadvances.2022007805"},{"key":"83550","doi-asserted-by":"crossref","unstructured":"McCluskey G, Heestermans M, Peyron I. A fully humanized von Willebrand disease type 1 mouse model as unique platform to investigate novel therapeutic options. Haematologica. 2024; 110(4):923-937.","DOI":"10.3324\/haematol.2024.286076"},{"key":"83551","doi-asserted-by":"crossref","unstructured":"Leong L, Byun T, Kim B. Preclinical characterization of VGA039, an anti-protein S monoclonal antibody being developed as a universal hemostatic agent for various bleeding disorders. Blood. 2022; 140:1666-1667.","DOI":"10.1182\/blood-2022-170245"},{"key":"83552","doi-asserted-by":"crossref","unstructured":"Gandhi PS, Zivkovic M, \u00d8stergarard H. HMB-001, a novel bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders. Nat Cardiovasc Res. 2024; 3(2):166-185.","DOI":"10.1038\/s44161-023-00418-4"},{"key":"83553","doi-asserted-by":"crossref","unstructured":"Roullet S, Luc N, Rayes J. Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in von Willebrand disease models. Blood. 2023; 141(23):2891-2900.","DOI":"10.1182\/blood.2022018956"},{"key":"83554","doi-asserted-by":"crossref","unstructured":"de Jong A, Dirven RJ, Boender J. Ex vivo improvement of a von Willebrand disease type 2A phenotype using an allele-specific small interfering RNA. Thromb Haemost. 2020; 120(11):1569-1579.","DOI":"10.1055\/s-0040-1715442"},{"key":"83555","doi-asserted-by":"crossref","unstructured":"Campioni M, Legendre P, Loubiere C. In vivo modulation of a dominant-negative variant in mouse models of von Willebrand disease type 2A. J Thromb Haemost. 2021; 19(1):139-146.","DOI":"10.1111\/jth.15131"},{"key":"83556","doi-asserted-by":"crossref","unstructured":"Linthorst NA, Jongejan YK, Dirven RJ. Amelioration of a von Willebrand disease type 2B phenotype in vivo upon treatment with allele-selective siRNAs. Blood Adv. 2024; 9(2):310-320.","DOI":"10.1182\/bloodadvances.2024014601"},{"key":"83557","doi-asserted-by":"crossref","unstructured":"Jongejan YK, Echeverri ES, Dirven RJ. Small interfering RNA-mediated allele-selective silencing of von Willebrand factor in vitro and in vivo. Blood Adv. 2023; 7(20):6108-6119.","DOI":"10.1182\/bloodadvances.2023010643"},{"key":"83558","doi-asserted-by":"crossref","unstructured":"Barbon E, Kawecki C, Marmier S. Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor. Gene Ther. 2023; 30(3-4):245-254.","DOI":"10.1038\/s41434-020-00218-6"},{"key":"83559","doi-asserted-by":"crossref","unstructured":"Lavin M, S\u00e1nchez Luceros A, Kouides P. Examining international practices in the management of pregnant women with von Willebrand disease. J Thromb Haemost. 2022; 20(1):82-91.","DOI":"10.1111\/jth.15561"},{"key":"83560","doi-asserted-by":"crossref","unstructured":"Kadir R, Lee C, Sabin C, Pollard D, Economides D. Pregnancy in women with von Willebrand\u2019s disease or factor XI deficiency. Br J Obstet Gynaecol. 1998; 105(3):314-321.","DOI":"10.1111\/j.1471-0528.1998.tb10093.x"},{"key":"83561","doi-asserted-by":"crossref","unstructured":"Delbr\u00fcck C, Miesbach W. The course of von Willebrand factor and factor VIII activity in patients with von Willebrand disease during pregnancy. Acta Haematol. 2019; 142(2):71-78.","DOI":"10.1159\/000496820"},{"key":"83562","doi-asserted-by":"crossref","unstructured":"Castaman G. Changes in von Willebrand factor during pregnancy in women with and without von Willebrand\u2019s disease. Mediterr J Hematol Infect Dis. 2013; 5(1):e2013052.","DOI":"10.4084\/mjhid.2013.052"},{"key":"83563","doi-asserted-by":"crossref","unstructured":"Huq F, Kulkarni A, Agbim E, Riddel A, Tuddenham E, Kadir R. Changes in the levels of factor VIII and von Willebrand factor in the puerperium. Haemophilia. 2011; 18(2):241-245.","DOI":"10.1111\/j.1365-2516.2011.02625.x"},{"key":"83564","doi-asserted-by":"crossref","unstructured":"James A, Konkle B, Kouides P, Ragni M, Thames B, Gupta S. Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis. Haemophilia. 2015; 21(1):81-87.","DOI":"10.1111\/hae.12568"},{"key":"83565","doi-asserted-by":"crossref","unstructured":"[No authors listed]. Management of inherited bleeding disorders in pregnancy: green-top guideline No. 71. BJOG. 2017; 124(8):e193-e263.","DOI":"10.1111\/1471-0528.14592"},{"key":"83566","doi-asserted-by":"crossref","unstructured":"Shahbazi S, Moghaddam-Banaem L, Ekhtesari F, Ala F. Impact of inherited bleeding disorders on pregnancy and postpartum hemorrhage. Blood Coag Fibrinolysis. 2012; 23(7):603-607.","DOI":"10.1097\/MBC.0b013e3283566af9"},{"key":"83567","doi-asserted-by":"crossref","unstructured":"Lak M, Peyvandi F, Mannucci P. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol. 2000; 111(4):1236-1239.","DOI":"10.1046\/j.1365-2141.2000.02507.x"},{"key":"83568","doi-asserted-by":"crossref","unstructured":"Skeith L, James P, Kouides P. VWD Pregnancy Loss Study Group. Pregnancy loss in individuals with von Willebrand disease and unspecified mucocutaneous bleeding disorders: a multicenter cohort study. J Thromb Haemost. 2025; 23(2):429-439.","DOI":"10.1016\/j.jtha.2024.09.037"},{"key":"83569","doi-asserted-by":"crossref","unstructured":"James A, Jamison M. Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease. J Thromb Haemost. 2007; 5(6):1165-1169.","DOI":"10.1111\/j.1538-7836.2007.02563.x"},{"key":"83570","doi-asserted-by":"crossref","unstructured":"Calleja-Agius J, Custo R, Brincat M, Calleja N. Placental abruption and placenta praevia. Eur Clinics Obstet Gynaecol. 2006; 2:121-127.","DOI":"10.1007\/s11296-006-0046-5"},{"key":"83571","doi-asserted-by":"crossref","unstructured":"Ito M, Yoshimura K, Toyoda N, Wada H. Pregnancy and delivery in patients with von Willebrand\u2019s disease. J Obstet Gynaecol Res. 1997; 23(1):37-43.","DOI":"10.1111\/j.1447-0756.1997.tb00803.x"},{"key":"83572","doi-asserted-by":"crossref","unstructured":"Briley A, Seed PT, Tydeman G. Reporting errors, incidence and risk factors for postpartum haemorrhage and progression to severe PPH: a prospective observational study. BJOG. 2014; 121(7):876-888.","DOI":"10.1111\/1471-0528.12588"},{"key":"83573","doi-asserted-by":"crossref","unstructured":"Tort J, Rozenberg P, Traor\u00e9 M, Fournier P, Dumont A. Factors associated with postpartum hemorrhage maternal death in referral hospitals in Senegal and Mali: a cross-sectional epidemiological survey. BMC Pregnancy Childbirth. 2015; 15:235.","DOI":"10.1186\/s12884-015-0669-y"},{"key":"83574","doi-asserted-by":"crossref","unstructured":"Punt M, Waning ML, Mauser-Bunschoten EP. Maternal and neonatal bleeding complications in relation to peripartum management in women with von Willebrand disease: a systematic review. Blood Rev. 2020; 39:100633.","DOI":"10.1016\/j.blre.2019.100633"},{"key":"83575","doi-asserted-by":"crossref","unstructured":"Castaman G, James P. Pregnancy and delivery in women with von Willebrand disease. Eur J Haematol. 2019; 103(2):73-79.","DOI":"10.1111\/ejh.13250"},{"key":"83576","doi-asserted-by":"crossref","unstructured":"Stoof S, van Steenbergen H, Zwagemaker A. Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey. Haemophilia. 2015; 21(4):505-512.","DOI":"10.1111\/hae.12635"},{"key":"83577","doi-asserted-by":"crossref","unstructured":"Punt M, van Leusden F, Bloemenkamp K. Primary postpartum hemorrhage in women with von Willebrand disease and carriers of hemophilia: a retrospective analysis. Res Pract Thromb Haemost. 2024; 8(5):102508.","DOI":"10.1016\/j.rpth.2024.102508"},{"key":"83578","doi-asserted-by":"crossref","unstructured":"Govorov I, L\u00f6fgren S, Chaireti R, Holmstr\u00f6m M, Bremme K, Mints M. Correction: postpartum hemorrhage in women with von Willebrand disease - a retrospective observational study. PLoS One. 2016; 12(2):e0172185.","DOI":"10.1371\/journal.pone.0172185"},{"key":"83579","doi-asserted-by":"crossref","unstructured":"Kulkarni A, Osmond M, Bapir M, Riddell A, Smith C. The effect of labour on the coagulation system in the term neonate. Haemophilia. 2013; 19(4):533-538.","DOI":"10.1111\/hae.12115"},{"key":"83580","doi-asserted-by":"crossref","unstructured":"Dupervil B, Abe K, O\u2019Brien SH. Characteristics, complications, and sites of bleeding among infants and toddlers less than 2 years of age with VWD. Blood Adv. 2021; 5(8):2079-2086.","DOI":"10.1182\/bloodadvances.2020004141"},{"key":"83581","doi-asserted-by":"crossref","unstructured":"Sanders Y, Fijnvandraat K, Boender J. Bleeding spectrum in children with moderate or severe von Willebrand disease: relevance of pediatric-specific bleeding. Am J Hematol. 2015; 90(12):1142-1148.","DOI":"10.1002\/ajh.24195"},{"key":"83582","doi-asserted-by":"crossref","unstructured":"Huq F, Kadir R. Management of pregnancy, labour and delivery in women with inherited bleeding disorders. Haemophilia. 2011; 17:Suppl-30.","DOI":"10.1111\/j.1365-2516.2011.02561.x"},{"key":"83583","doi-asserted-by":"crossref","unstructured":"Jawad A. Tranexamic acid for antenatal bleeding of unknown origin in the second and third trimesters: a prospective clinical trial. Zanco J Medl Sci. 2021; 25(2):532-543.","DOI":"10.15218\/zjms.2021.017"},{"key":"83584","unstructured":"Sharma R., Chatterjee S., Kapur A, Pandit S. To study the effect of tranexamic acid in early pregnancy bleeding in post IVF pregnancies: a prospective observational study. Int J Curr Adv Res. 2019; 8(11):20494-20497."},{"key":"83585","doi-asserted-by":"crossref","unstructured":"Mirza F, Abdul-Kadir R, Breymann C, Fraser I, Taher A. Impact and management of iron deficiency and iron deficiency anemia in women\u2019s health. Exp Rev Hematol. 2018; 11(9):727-736.","DOI":"10.1080\/17474086.2018.1502081"},{"key":"83586","doi-asserted-by":"crossref","unstructured":"Ruppen W, Derry S, McQuay H, Moore RA. Incidence of epidural hematoma, infection, and neurologic injury in obstetric patients with epidural analgesia\/anesthesia. Anesthesiology. 2006; 105(2):394-399.","DOI":"10.1097\/00000542-200608000-00023"},{"key":"83587","doi-asserted-by":"crossref","unstructured":"Laffan M, Lester W, O\u2019Donnell J, Will A, Tait R, Goodeve A. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol. 2014; 167(4):453-465.","DOI":"10.1111\/bjh.13064"},{"key":"83588","doi-asserted-by":"crossref","unstructured":"Bouthors AS, England A, Kadir RA. Analgesia and anaesthesia for pregnant women with inherited bleeding disorders. In: Inherited Bleeding Disorders in Women, Second Edition. 2019;191-202.","DOI":"10.1002\/9781119426080.ch12"},{"key":"83589","doi-asserted-by":"crossref","unstructured":"Janbain M, Kouides P. Managing pregnant women with haemophilia and VWD; how we provide optimum care and prevent complications. Intl J Womens Health. 2022; 14:1307-1313.","DOI":"10.2147\/IJWH.S273043"},{"key":"83590","doi-asserted-by":"crossref","unstructured":"Al Arashi W, Romano L, Leebeek F. Desmopressin to prevent and treat bleeding in pregnant women with an inherited bleeding disorder: a systematic literature review. J Thromb Haemost. 2024; 22(1):126-139.","DOI":"10.1016\/j.jtha.2023.09.021"},{"key":"83591","doi-asserted-by":"crossref","unstructured":"Machin N, Ragni M. Recombinant vs plasma-derived von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease. Blood Adv. 2020; 4(14):3234-3238.","DOI":"10.1182\/bloodadvances.2020002046"},{"key":"83592","doi-asserted-by":"crossref","unstructured":"Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen D. Development of the human coagulation system in the full-term infant. Blood. 1987; 70(1):165-172.","DOI":"10.1182\/blood.V70.1.165.bloodjournal701165"},{"key":"83593","doi-asserted-by":"crossref","unstructured":"van Kwawegen CB, Fijnvandraat K, Kruip MJH. Patient-reported data on the severity of von Willebrand disease. Haemophilia. 2024; 30(6):1348-1356.","DOI":"10.1111\/hae.15103"},{"key":"83594","doi-asserted-by":"crossref","unstructured":"Kuaban A, Croker AK, Keefer J. The roadmap to integrate diversity, equity, and inclusion in hematology clinical trials: an American Society of Hematology initiative. Blood Adv. 2024; 9(4):687-694.","DOI":"10.1182\/bloodadvances.2024013945"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286059\/79200","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286059\/79262","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/13058\/79200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:10:43Z","timestamp":1794046243000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.286059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":118,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286059","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,11]]}}}